ReviewJournal of molecular medicine (Berlin, Germany)2019
Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
Review in Journal of molecular medicine (Berlin, Germany), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07360977 (A Composition Comprising Glucoraphanin, Myrosinase and a Buffered Solution for Use in the Treatment of Neurodegenerative Diseases), which is not on this map. Cited by 54 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Composition Comprising Glucoraphanin, Myrosinase and a Buffered Solution for Use in the Treatment of Neurodegenerative Diseases
Who cites it
54 citing papers in PubMed, 1 synthesis or guideline pooled it, 122 citations in OpenAlex.
- Efficacy and safety of disease-modifying oral drugs in treatment of relapsing-remitting multiple sclerosis: systematic review and network meta-analysis.Frontiers in immunology · 2026Pooled it
- Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study.Annals of clinical and translational neurology · 2021Trial
- PET-MRI effects of N-acetylcysteine in patients with multiple sclerosis.IBRO neuroscience reports · 2026Article
- Mucoadhesive Nanoemulsions for Nose-to-Brain Delivery of Dimethyl Fumarate: Development, Characterization and Proof-of-Concept In Vivo Evaluation.Pharmaceutics · 2026Article
- Neuroprotective effects of glucotropaeolin as the major glucosinolate of cress seed on cuprizone-induced mouse model of multiple sclerosis.Biochemistry and biophysics reports · 2026Article
- Attenuation of Experimental Bronchopulmonary Dysplasia by Dimethyl Fumarate.Pediatric research · 2026Article
- The NLRP3 Inflammasome in Neuropsychiatric Disorders: Molecular Mechanisms and Emerging Therapeutic Strategies.International journal of molecular sciences · 2026Review
- NRF2 agonists 4-octyl-itaconate and dimethyl fumarate reduce human and bovine RSV proliferation and RSV disease in a murine model.ImmunoHorizons · 2025Article
- Epigenetic and Mitochondrial Metabolic Dysfunction in Multiple Sclerosis: A Review of Herbal Drug Approaches and Current Clinical Trials.Molecular neurobiology · 2025Review
- Plasma microRNA Signature as Predictive Marker of Clinical Response to Therapy During Multiple Sclerosis.Annals of clinical and translational neurology · 2025Article
- Comparative Neurotoxic Effects of Doxorubicin and Sunitinib: An In Vitro Study on Human Dopaminergic Neuronal Cells.Molecules (Basel, Switzerland) · 2025Article
- Real-world infection risk in multiple sclerosis patients on long-term immunomodulatory treatments.Multiple sclerosis and related disorders · 2025Observational
- Immunomodulatory effects of HYCO-3, a dual action CO-releaser/Nrf2 activator.Clinical and experimental immunology · 2025Article
- Identification of novel antiviral host factors by functional gene expression analysis using in vitro HBV infection assay systems.PloS one · 2025Article
- Cytomegalovirus Infection in a Multiple Sclerosis Patient on Dimethyl Fumarate.Case reports in neurological medicine · 2025Article
- Hybrid derivatives containing dimethyl fumarate and benzothiazole scaffolds for the potential treatment of multiple sclerosis; in silico & in vivo study.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Article
- Lutein improves remyelination by reducing of neuroinflammation in C57BL/6 mouse models of multiple sclerosis.Heliyon · 2024Article
- The role of oxidative stress in blood-brain barrier disruption during ischemic stroke: Antioxidants in clinical trials.Biochemical pharmacology · 2024Review
- Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects.Pharmacological reports : PR · 2024Review
- The Effect of NF-κB Deactivation on Cancer Cell Response to ALA Mediated Photodynamic Therapy.Asian Pacific journal of cancer prevention : APJCP · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dimethyl fumarate (DMF) is an oral, disease-modifying agent for the treatment of relapsing-remitting multiple sclerosis (RRMS). However, details regarding its mode of action are still emerging. It is believed that the mode of action of DMF involves both nuclear factor erythroid-derived 2-related factor (Nrf2)-dependent and independent pathways, which lead to an anti-inflammatory immune response due to type II myeloid cell and Th2 cell differentiation and neuroprotection. In this review, we will focus on the molecular and signaling effects of DMF that lead to changes in peripheral immune cell composition and function, alteration in CNS cell-specific functions, and effect on the blood-brain barrier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.